Event-driven litigation continues to fuel the rise of securities class actions against public companies, and that has certainly been the case with COVID-19 related litigation. Pandemic-related events have formed the basis for...more
12/2/2020
/ Chamber of Commerce ,
Class Action ,
Coronavirus/COVID-19 ,
Cruise Ships ,
Enforcement Actions ,
Misleading Statements ,
Pharmaceutical Industry ,
Popular ,
Publicly-Traded Companies ,
Securities and Exchange Commission (SEC) ,
Securities Litigation
Life sciences companies were popular targets of class action securities lawsuits in 2018.
In the most recent edition of our annual survey, Dechert litigators David H. Kistenbroker, Joni S. Jacobsen and Angela M. Liu examine...more
2/13/2019
/ Anti-Kickback Statute ,
Class Action ,
Clinical Trials ,
FDA Approval ,
Fraud ,
Life Sciences ,
Material Misstatements ,
Mismanagement ,
Misrepresentation ,
Popular ,
Risk Management ,
Risk Mitigation ,
Securities Fraud ,
Securities Litigation ,
Stock Drop Litigation ,
Surveys
Life sciences companies continued to be popular targets of securities fraud class action lawsuits filed in 2016, and prudent life sciences companies should take heed of the results of this year’s decisions. In 2016,...more
3/9/2017
/ Antitrust Violations ,
Class Action ,
Drug Pricing ,
False Statements ,
FDA Approval ,
Generic Drugs ,
Life Sciences ,
Material Misrepresentation ,
Omissions ,
Popular ,
Price-Fixing ,
Promotional Items ,
Risk Mitigation ,
Securities Fraud ,
Stock Drop Litigation